Lantern Pharma Inc (LTRN)
$5.72
+0.38
(+7.12%)▲
Insights on Lantern Pharma Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 45.1% return, outperforming this stock by 27.9%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 238.3% return, outperforming this stock by 303.7%
Performance
- $5.25$5.98$5.72
8.22%
Downside
Day's Volatility :12.21%
Upside
4.35%
- $2.38$10.77$5.72
58.39%
Downside
52 Weeks Volatility :77.9%
Upside
46.89%
Returns
| Period | Lantern Pharma Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 38.5% | -0.4% | 0.0% |
6 Months | 110.68% | 9.6% | 0.0% |
1 Year | 23.28% | 3.9% | -1.3% |
3 Years | -65.44% | 12.8% | -22.1% |
Highlights
Market Capitalization | 57.4M |
Book Value | $3.82 |
Earnings Per Share (EPS) | -1.47 |
Wall Street Target Price | 18.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -21.81% |
Return On Equity TTM | -32.93% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -17.9M |
Diluted Eps TTM | -1.47 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.03 |
EPS Estimate Next Year | -1.88 |
EPS Estimate Current Quarter | -0.4 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 214.69%
Technicals Summary
Sell
Neutral
Buy
Lantern Pharma Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Lantern Pharma Inc | -42.34% | 110.68% | 23.28% | -65.44% | -61.74% |
 Moderna, Inc. | -5.36% | 32.83% | -24.38% | -39.84% | 322.91% |
 Regeneron Pharmaceuticals, Inc. | -6.34% | 13.15% | 12.94% | 84.22% | 161.57% |
 Novo Nordisk A/s | -2.94% | 28.97% | 46.95% | 238.27% | 414.84% |
 Vertex Pharmaceuticals Incorporated | -3.87% | 8.77% | 20.15% | 83.53% | 128.04% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Lantern Pharma Inc | NA | NA | NA | -2.03 | -0.33 | -0.22 | NA | 3.82 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.77 | 25.77 | 1.46 | 45.22 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.13 | 46.13 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.39 | 28.39 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Lantern Pharma Inc | Sell | $57.4M | -61.74% | NA | 0.0% |
Moderna, Inc. | Buy | $38.8B | 322.91% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.4B | 161.57% | 25.77 | 30.14% |
Novo Nordisk A/s | Buy | $551.3B | 414.84% | 46.13 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 128.04% | 28.39 | 36.68% |
Institutional Holdings
Vanguard Group Inc
3.40%Goss Wealth Management LLC
1.54%Geode Capital Management, LLC
0.88%CM Management, LLC
0.74%Carlson Capital LP
0.56%Commonwealth Equity Services Inc
0.55%
Corporate Announcements
Lantern Pharma Inc Earnings
Lantern Pharma Inc’s price-to-earnings ratio stands at None
Read More
Company Information
lantern pharma is leading a wave of innovation in cancer treatment that we believe will bring the best therapies to patients who are most likely to respond. we are pioneering precision medicine approach to cancer by tailoring promising drug programs to the right patients. our approach is to use biomarker based genetic screening to identify and treat patients that would benefit most from our drugs. we believe this approach will reduce the cost of development and increase the speed to market. our strategy is to acquire or partner with promising drug and diagnostic companies to move forward promising personalized medicine programs for cancer patients.
Organization | Lantern Pharma Inc |
Employees | 21 |
CEO | Mr. Panna Sharma PH.D. |
Industry | Commercial Services |
